Details for Patent: 8,058,267

Which drugs does patent 8,058,267 protect, and when does it expire?

Patent 8,058,267 protects OCALIVA and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: 8,058,267

Title:	Steroids as agonists for FXR
Abstract:	The invention relates to compounds of formula (I): ##STR00001## wherein R is ethyl and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
Inventor(s):	Pellicciari; Roberto (Perugia, IT)
Assignee:	Intercept Pharmaceuticals, Inc. (New York, NY)
Application Number:	12/547,147
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,058,267

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016		RX	Yes	No						TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016		RX	Yes	Yes						TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)

International Family Members for US Patent 8,058,267

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	303399
Australia	2002308295
Canada	2440680
Germany	60205891
Denmark	1392714